Matches in Nanopublications for { ?s ?p "[Based on methylation in primary tumors compared to normal adjacent tissues, NKX2-5, CLSTN1, SPOCK2, SLC16A12, DPYS and NSE1 are candidate biomarkers for prostate cancer (methylation range 50%-85%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP668560.RAY4elIxKf9FlWI8Hz4L-ajEPR3c7fJKwhDOzTM70fCnw130_assertion description "[Based on methylation in primary tumors compared to normal adjacent tissues, NKX2-5, CLSTN1, SPOCK2, SLC16A12, DPYS and NSE1 are candidate biomarkers for prostate cancer (methylation range 50%-85%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP668560.RAY4elIxKf9FlWI8Hz4L-ajEPR3c7fJKwhDOzTM70fCnw130_provenance.
- NP668563.RANBwcW7Lc_1wni6WxyHULLsz-Ap-gvSlld5gYULsMsao130_assertion description "[Based on methylation in primary tumors compared to normal adjacent tissues, NKX2-5, CLSTN1, SPOCK2, SLC16A12, DPYS and NSE1 are candidate biomarkers for prostate cancer (methylation range 50%-85%).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP668563.RANBwcW7Lc_1wni6WxyHULLsz-Ap-gvSlld5gYULsMsao130_provenance.